NOVADIGM THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.novadigm.net
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
Phase 2
Completed
- Conditions
- Staphylococcus Aureus
- Interventions
- Biological: NDV-3ABiological: Placebo
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT03455309
- Locations
- 🇺🇸
Fort Benning, Fort Benning, Georgia, United States
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1
Completed
- Conditions
- Vulvovaginal Candidiasis
- Interventions
- Biological: PlaceboBiological: NDV-3ABiological: NDV-3
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT01926028
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Suffolk Ob/Gyn, Port Jefferson, New York, United States
🇺🇸McCann MD Research, Inc., Torrance, California, United States
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
Phase 1
Completed
- Conditions
- Staphylococcal InfectionsYeast InfectionsCandidiasis
- Interventions
- Biological: NDV-3 vaccine without alum IDBiological: NDV-3 vaccine without alum IMBiological: Placebo with alum IMBiological: NDV-3 vaccine with alum IM
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT01447407
- Locations
- 🇺🇸
Cetero Research Clinical Site, Fargo, North Dakota, United States
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
Phase 1
Completed
- Conditions
- Staphylococcal InfectionsCandidiasis
- Interventions
- Biological: NDV-3 investigational vaccine
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01273922
- Locations
- 🇺🇸
Cetero, Fargo, North Dakota, United States
© Copyright 2025. All Rights Reserved by MedPath